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Abstract- Postconditioning is a simple and safe strategy for cardioprotection and infarct size limitation. Our 
previous study showed that oxytocin (OT) exerts postconditioning effect on ischemic/reperfused isolated rat 
heart. The aim of this study was to investigate the involvement of OT receptor, mitochondrial ATP-sensitive 
potassium channel (mKATP), nitric oxide (NO) and cyclooxygenase (COX) pathways in OT 
postconditioning. Isolated rat hearts were divided into10 groups and underwent 30 min of regional ischemia 
followed by 120 min of reperfusion (n =6). In I/R (ischemia/reperfusion) group, ischemia and reperfusion 
were induced without any treatment. In OT group, oxytocin was perfused 5 min prior to beginning of 
reperfusion for 25 min. In groups 3-6, atosiban (oxytocin receptor blocker), L-NAME (N-Nitro-L-Arginine 
Methyl Ester, non-specific nitric oxide synthase inhibitor), 5-HD (5-hydroxydecanoate, mKATP inhibitor) 
and indomethacin (cyclooxygenase inhibitor) were infused prior to oxytocin administration. In others, the 
mentioned inhibitors were perfused prior to ischemia without oxytocin infusion. Infarct size, ventricular 
hemodynamic, coronary effluent, malondialdehyde (MDA) and lactate dehydrogenase (LDH) were measured 
at the end of reperfusion. OT perfusion significantly reduced infarct size, MDA and LDH in comparison with 
IR group. Atosiban, 5HD, L-NAME and indomethacin abolished the postconditioning effect of OT. Perfusion 
of the inhibitors alone prior to ischemia had no effect on infarct size, hemodynamic parameters, coronary 
effluent and biochemical markers as compared with I/R group. In conclusion, this study indicates that 
postconditioning effects of OT are mediated by activation of mKATP and production of NO and 
Prostaglandins (PGs). 
© 2015 Tehran University of Medical Sciences. All rights reserved.  
Acta Med Iran 2015;53(8):491-500.  
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Introduction 
 
Rapid reperfusion of the ischemic myocardium is a 
valuable approach to decrease infarct size. However, 
reperfusion by itself leads to reversible and irreversible 
injuries in the ischemic myocardium (1-2). To decrease 
reperfusion injuries in the ischemic myocardium, 
postconditioning, as a cardioprotective phenomenon, is 
induced at the end of ischemia and early reperfusion by 
using the repetitive short periods of 
ischemia/reperfusion (I/R) or by administration of 
pharmacological agents (3-4). 
Myocardial infarct-limiting effects of 
postconditioning have been reported to be sensitive to 
inhibition of the NO-cyclic GMP (cGMP)-dependent 
protein kinase G (NO-cGMP-PKG) signaling pathway 
which has protective role against I/R injuries (5). 
Recently it has been reported that nitric oxide (NO) is 
involved in cardiac postconditioning (6). Administration 
of L-NAME prior to the onset of reperfusion abolished 
the cardioprotection induced by ischemic postconditiong 
(6). Also, the role of NO was reported in the heart 
failure and left ventricular remodeling (7). In a previous 
study, we showed that oxytocin-induced preconditioning 
was mediated by NO (8). It has also been shown that 
postconditioning leads to release of endogenous ligands 
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and activates G-protein-coupled receptor and then 
stimulates intracellular signaling pathway that may 
terminate on mitochondrial ATP-sensitive potassium 
channel (mKATP) and permeability transition pore 
(mPTP) (9-10).  At mitochondria, PKG can open the 
mKATP via protein kinase C-ε (PKC-ε) (9). 
Postconditioning has an antioxidant effect and can 
decrease oxidative stress by reduction of the superoxide 
(11). It also induces activation of guanylyl cyclase; 
activate the reperfusion injury signaling kinase (RISK), 
extracellular regulated kinase-1 (ERK1/2), and PI3k/Akt 
signaling pathways (12,13). Postconditioning also 
increases expression and activation of the 
phosphorylated endothelial nitric oxide synthase (p-
eNOS). Activation of NOS through the production of 
cGMP and activation of PKG could open mKATP and  
leads to cardioprotection (14). 
Prostaglandins (PGs) have a putative role in 
cardioprotection and reduction of myocardial injuries 
such as infarct size in the rat model of myocardial I/R 
injury (15). Also, there were increased cardiac I/R 
injuries in COX-1 and COX-2 knockout mice in 
coronary artery ligation model (16-17). Then, it suggests 
that COX-1 and COX-2 signaling pathways may be 
involved in the cardioprotection (16-18). Birnbaum 
showed that PGs are essential for mediating 
cardioprotective effects of atorvastatin (15). Berti (19) 
and Rossoni (20) also reported indomethacin and aspirin 
can increase ischemia-induced ventricular dysfunction in 
perfused rabbit hearts, therefore this effect was related to 
inhibition of prostacyclin (PGI2) synthesis in the 
myocardium. PGI2 production is increased during the 
early 5–10 min of reperfusion and then declined during 
more reperfusion (21). In addition, it is reported that 
administration of opioids or anesthetic agents through 
COX-2 up-regulation leads to cardioprotection (22). It 
has been shown that activation of OT receptor can lead 
to PGs production (23-24), and decrease I/R injuries.  
Oxytocin (OT) as a cardiovascular hormone is 
synthesized and released in the heart, and large vessels, 
and systemic administration of exogenous OT shows 
some cardiovascular functions (25-26). Some experiments 
showed that atosiban (a blocker of oxytocin receptor) can 
inhibit OT effects on heart function (27-28). Recently we 
reported that infusion of OT at the end of ischemia and 
early reperfusion period, postconditioned the isolated rat 
heart against I/R injury (29). It has been shown that in the 
cardiovascular system, OT receptor can activate atrial 
natriuretic peptide (ANP) and NO-cGMP signaling 
pathways (30). OT can also activate PKC in 
cardiomyocytes (31). On the other hands, PKC activation 
promotes mKATP channels opening in rat heart and 
induces cardioprotection (32). 
The aim of this study was to determine the possible 
role of oxytocin receptor, mKATP channel, nitric oxide 
and prostaglandins in the postconditioning effects of 
oxytocin in the ischemic/reperfused isolated rat heart. 
   
Materials and Methods 
 
Experimental animals and ethical approval 
Male wistar rats weighing 250–300g were housed in 
an animal room with 12h light/dark cycle at 22 ± 2°C 
and free access to food and water. Animals were adapted 
for at least seven days before the experiments. The 
experimental protocol was approved by the institutional 
care and use committee of Tehran University of Medical 
Sciences (Tehran, Iran). 
  
Preparation of isolated hearts 
The animals were anesthetized with sodium 
pentobarbital (50mg/kg, i.p.) and given heparin sodium 
(500IU). The hearts were excised quickly and placed in 
an ice-cold buffer, then attached to Langendorff 
apparatus for their perfusion. Hearts were perfused with 
modified Krebs–Henseleit bicarbonate buffer 
containing: NaHCO3 25; KCl l4.7; NaCl 118.5; MgSO4 
1.2; KH2PO4 1.2; glucose 11; CaCl2 2.5 (in mmol/l) 
and gassed with 95% O2, 5% CO2 (pH 7.35–7.45 at 
37°C). Heart temperature was kept constant during the 
experiment with a water-jacketed closed system. A 
fluid-filled latex balloon was inserted into the left 
ventricle via the left atrium and connected to a pressure 
transducer (Harvard). Left ventricular systolic and 
diastolic pressures and heart rate were measured 
throughout the experimental protocols via a custom 
designed chart recorder (Oscillograph Monitor, Biomed, 
Tehran, Iran). The left ventricular end-diastolic pressure 
(LVEDP) was adjusted to 5-10 mmHg by filling the 
balloon with water and was not changed afterward. 
A 6-0 silk suture was passed below the origin of the 
left anterior descending coronary artery (LAD), and the 
ends of the suture were passed through a pipette tip to 
form a snare. Regional ischemia was accomplished by 
pulling the snare. Reperfusion was performed by 
releasing the ends of the suture. Hearts were allowed to 
beat spontaneously during the experiments. Left 
ventricular developed pressure (LVDP) was calculated 
as left ventricular systolic pressure minus left ventricular 
end diastolic pressure (LVDP=LVSP−LVEDP). Left 
ventricular function was assessed by rate pressure 
product (RPP=HR×LVDP). Coronary effluent was 
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collected for assessment of lactate dehydrogenase 
(LDH) and malondialdehyde (MDA) at the end of 
reperfusion. 
 
Experimental protocol 
Before 15 min baseline period, each heart was 
allowed to stabilize for 20 min. The hearts in all groups 
were subjected to 30 min of regional ischemia followed 
by 120 min of reperfusion. Atosiban (oxytocin receptor 
blocker), L-NAME (N-Nitro-L-Arginine Methyl Ester, 
non-specific nitric oxide synthase inhibitor), 5-HD (5-
hydroxydecanoate, mKATP inhibitor) and indomethacin 
(cyclooxygenase inhibitor) were used in this study. The 
hearts were randomized into one of ten groups (n=6): 1) 
ischemia/reperfusion (IR) group; hearts subjected to 30 
min of regional ischemia followed by 120 min of 
reperfusion without any treatment. 2) OT group; 
Oxytocin (10-11M, optimum dose of OT was achieved 
by our previous study (29)) was perfused 5 min prior to 
reperfusion for 25 min; 3) ATO group; Atosiban (10-8 
M) was perfused 10 min before ischemia for 10 min; 4) 
ATO+OT group; Atosiban was perfused 35 min before 
OT perfusion; 5) 5HD group; 5-HD (10-6 M) was 
perfused 10 min before ischemia for 10 min; 6) 
5HD+OT group: 5HD was perfused 35 min before OT 
perfusion; 7) L-NAME group; L-NAME (10-6M) was 
perfused 10 min before ischemia for 10 min; 8) L-
NAME+OT group; L-NAME was perfused 35 min 
before OT perfusion; 9) INDO group; Indomethacin (10-
6M) was perfused 10 min before ischemia for 10 min; 
10) INDO+OT group; Indomethacin was perfused 35 
min before OT perfusion (Figure 1). 
 
 
Figure 1. Schematic illustration of experimental groups 
IR, Ischemia/Reperfusion; OT, Oxytocin; ATO, Atosiban; 5HD, 5-hydroxydecanoic acid; INDO, Indomethacin 
 
Measurement of infarct size  
After 120 min of reperfusion, LAD was re-occluded, 
and Evans blue dye (2%) was infused through the aorta to 
differentiate the ischemic area from the non-ischemic 
area. Hearts were frozen at -20°C for 24h and then sliced 
into 2 mm transverse sections. Slices then incubated in 
1% 2, 3, 5 triphenyl tetrazolium chloride (TTC in 0.1M 
phosphate buffer, pH 7.4) for 15-20 min at 37°C. TTC 
reacts with the viable tissue, producing a red formazan 
derivative, which is distinct from the white necrotic area 
when placed in 10% formalin for several days. The area at 
risk (ischemic zone) and infarcted area were calculated by 
Photoshop program (Ver. 7.0, Adobe System, San Jose, 
CA, USA). The area at risk was expressed as a percentage 
of the left ventricle (AAR/LV), and infarct size was 
expressed as a percentage of area at risk (IS/AAR). 
 
Measurement of LDH and MDA  
LDH and MDA levels were measured in coronary 
effluent at the end of 120 min reperfusion. LDH (a 
marker of myocyte necrosis) was determined with LDH 
Kit (Pars Azmoon, Teheart ratean, Iran), using an 
autoanalyzer (Roche Hitachi Modular DP Systems; 
Mannheim, Germany). MDA (a marker of lipid 
peroxidation) was assessed by a thiobarbituric acid 
(TBA) method. In brief, 1.5ml of perfusate fluid was 
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added to 0.5 ml of a solution containing 30% 
trichloroacetic acid, 0.75% TBA, and 0.5 NHCl, and 
then incubated in a 100°C for 20 min. After cooling, the 
samples were centrifuged, and MDA level was read by 
spectrophotometer at 532 nm (33). 
 
Drugs and reagents 
Oxytocin, atosiban, 5-HD, L-NAME, indomethacin, 
2, 3, 5 triphenyl tetrazolium chlorides (TTC) and Evans 
blue were obtained from Sigma Chemical Co. 
 
Statistical analyses 
Data are expressed as means ± SEM. Statistical 
comparison of means between groups was made by one-
way ANOVA and a subsequent Tukey test for infarct 
size ratio and biochemical parameters. Statistical 
analysis of hemodynamic data within and between 
groups was performed with Two-way ANOVA. 
Statistical significance was defined as P<0.05. 
 
Results 
 
Hemodynamic function 
Table 1 shows HR, RPP and LVDP changes during 
the experiments. LVDP and RPP were expressed as a 
percentage of their baseline. HR, RPP, and LVDP were 
decreased significantly in all groups at the end of 
ischemia and reperfusion compared to their baseline 
(P<0.05), but not significant differences were shown 
between experimental groups at baseline, end of 
ischemia and reperfusion. 
 
Infarct size and area at risk 
Statistical analysis showed that there were no 
significant differences in the ratio of the area at risk to 
the total left ventricular area (AAR/LV %) between the 
hearts in all groups. The ratio of infarct size to area at 
risk (IS/AAR %) significantly decreased from 36.35 ± 
0.48 in I/R group to 11.68±0.86 (P<0.05) in OT group 
(Figure 2).  
 
 
Figure 2. Myocardial infarct size in different groups (n=6) 
AAR, Area At Risk; IS, Infarct Size; LV, Left Ventricle; IR, Ischemia/Reperfusion; OT, Oxytocin; ATO, Atosiban; 5HD,5-hydroxydecanoic 
acid; INDO, Indomethacin. Data are presented as mean ± SEM. *P<0.05 vs. IR group and $P<0.05 vs. OT group 
 
Administration of atosiban in ATO+OT group, 5HD 
in 5HD+OT group, L-NAME in L-NAME+OT group 
and Indomethacin in INDO+OT group increased infarct 
size to 32.27 ± 2.8, 31.19 ±3, 32.36±1.2 and 27.23±1.76,  
respectively in comparison with OT group (P<0.05). 
Atosiban, 5HD, L-NAME, and INDO alone had no 
significant effect on infarct size. There were no 
significant differences in ATO+OT, ATO, 5HD+OT, 
5HD, L-NAME+OT, L-NAME, INDO+OT and INDO 
groups compared to IR group. 
 
Biochemical analysis 
The levels of LDH and MDA in coronary effluent 
were used to monitor the damages of the myocardium. 
LDH level in coronary effluent significantly decreased 
in OT group (53.14±10.97) compared to IR group 
(232.125±21.5) (P<0.05 Figure 3). Administration of 
ATO in ATO+OT group, 5HD in 5HD+OT group, L-
NAME in L-NAME+OT group and Indomethacin in 
INDO+OT group significantly increased LDH levels 
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(172.125±22.6, 169.125±13.301, 186.75±8.6 and 
171.5±16.5 respectively) in comparison with OT group 
(P<0.05). There were no significant differences in 
ATO+OT, ATO, 5HD+OT, 5HD, L-NAME+OT, L-
NAME, INDO+OT and INDO groups compared to IR 
group. 
 
 
Figure 3. Levels of LDH in coronary effluent at the end of reperfusion period in different groups (n=6) 
IR, Ischemia/Reperfusion; OT, Oxytocin; ATO, Atosiban; 5HD, 5-hydroxydecanoic acid; INDO, Indomethacin. Data are presented as 
mean±SEM. *P<0.05 vs. IR group and $P<0.05 vs. OT group. 
 
MDA levels in coronary effluent significantly 
decreased in OT group (1.27±0.299) in comparison with 
IR group (5±0.37) (P<0.05 Fig.4). Administration of 
ATO in ATO+OT group, 5HD in 5HD+OT group, L-
NAME in L-NAME+OT group and Indomethacin in 
INDO+OT group increased MDA (4.7±0.51, 
5.375±0.744, 4.82±0.45 and 5.3±0.67 respectively) 
compared to OT group (P<0.05 Fig.4). There were no 
significant differences in ATO+OT, ATO, 5HD+OT, 
5HD, L-NAME+OT, L-NAME, INDO+OT and INDO 
groups compared to IR group. 
 
 
Figure 4. Levels of MDA in coronary effluent at the end of reperfusion period in different groups (n=6) 
IR, Ischemia/Reperfusion; OT, Oxytocin; ATO, Atosiban; 5HD, 5-hydroxydecanoic acid; INDO, Indomethacin.  
Data are presented as mean±SEM  
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Discussion 
 
Postconditioning is an easy and safe strategy which 
provides a new method to protect organs from I/R 
injury, such as heart and liver (34). Our previous study 
demonstrated that OT has a postconditioning effect on 
the isolated rat heart. OT administration at the end of 
ischemia and the beginning of reperfusion dose 
dependently protected isolated rat heart from I/R injury 
(29). 
In this study, administration of OT had no significant 
effect on hemodynamic parameter (such as; HR, LVDP, 
and RPP) compared to IR group and it seems that 
cardioprotective effect of OT is not related to changes in 
hemodynamic parameters. In the other hand, OT 
significantly decreased infarct size, LDH, and MDA 
level compared to IR group. These cardioprotective 
effects were abolished by administration of atosiban, as 
a non-selective OT-receptor antagonist, 5HD, as an 
mKATP channel blocker, L-NAME, inhibitor of NO 
production, and indomethacin as an inhibitor of PGs 
production. According to current findings, it seems that 
OT postconditioning can occur through stimulation of 
oxytocin receptor, PGs release, NO production and 
opening of mKATP channel and leads to 
cardioprotection against ischemia/reperfusion injury. 
It has been shown that ROS play a crucial role in the 
I/R injury. After ischemia, ROS were produced at the 
onset of reperfusion (34-35). In the present study, OT 
administration prevented the MDA level raise and it 
appears that OT by reducing oxidative stress attenuates 
myocardial injury. OT reverses the increased level of 
MDA to a considerable extent, that confirms its 
antioxidant effect on I/R injury. Biyikli et al., reported 
that OT attenuates oxidative renal damage in 
pyelonephritic rats through its antioxidant effect (36). 
NO can activate antioxidant defense via formation of 
intracellular antioxidants (37) and decrease ROS 
release via inhibition of NADPH oxidase activity (34). 
NO is involved in the cardioprotection induced by 
postconditioning (6 9,34,38). It has been shown that 
NO acts as a postconditioning trigger in 
ischemic/reperfused heart (5,9,34). cGMP is the 
downstream signaling target of NO, which by 
activating of PKG and opening of the mKATP channel 
leads to reducing post-ischemic Ca2+ overload 
(5,9,13,39). Different cellular effects of NO may 
depend on its concentration, site of release and 
duration of action. Low levels of NO may have 
protective effects, but high levels may be detrimental. 
In I/R injury, NO may have a dual function. In one 
hand, it reacts with superoxide anions and converts to 
the cytotoxic oxidant peroxynitrite. On the other hand, 
NO can decrease neutrophil infiltration, reduce infarct 
size and decrease coronary vascular endothelium 
damages (6,13,38,40). Current findings support the 
role of endogenous NO, in OT protection specifically 
during the early reperfusion period. In this regard, 
Burley and Baxter showed that administration of B-
type Natriuretic Peptide (BNP) during the early phase 
of reperfusion decreases infarct size and the 
cardioprotective effect of BNP is likely due to 
endogenous NOS/NO activity (39). Krolikowski et al., 
reported that eNOS but not iNOS or nNOS mediates 
cardioprotection by isoflurane during the early phase of 
reperfusion (41). It has also been reported that OT have 
renal protective effect against I/R injury with reduction 
of lipid peroxidation that is mediated by NO 
production (42). Postconditioning can reduce the free 
radical formation, and consequently postconditioning-
 
Table1. Hemodynamic Parameters 
Group 
Baseline End of ischemia End of reperfusion 
HR 
(Beats/min) 
HR 
(Beats/min) 
LVDP 
(Baseline/min)
RPP 
(Baseline/min)
HR 
(Beats/min)
LVDP 
(%Baseline) 
RPP 
(%Baseline)
IR  205±3.7 155.3±11* 74.7±4.5* 75.8±4.6* 118.2±17.2* 54.4±6.9* 32.8±6.8* 
OT 221.9±8.5 172.7±17* 69.5±8.2* 64.7±5.6* 150.1±9.1* 59.7±1* 39.2±2.5* 
ATO-OT 232±17 176.5±16* 72.9±3.5* 56.3±4.1* 135±18* 46.2±2.4* 29.3±2.7* 
ATO 241±20 169±12* 69.4±3.5* 59.5±3.6* 132±15* 44.5±2.3* 28.6±4* 
5HD-OT 222.5±12 156±10* 68.8±2.6* 58.3±6.4* 107±18* 47.6±4.7* 27.7±2.7* 
5-HD 245±16 170±21* 68.9±3.5* 60.9±4.8* 129±9* 48.4±2.8* 29±3.1* 
L-NAME-OT 237.7±13.2 176.8±9.1* 73.9±3* 59.9±3.3* 129.7±10.8* 48±1.9* 28.6±2.2* 
L-NAME 239.3±21.4 173.6±11.2* 67.2±3.6* 61.1±4* 127±10.3* 43.5±2.3* 30.8±2.8* 
INDO-OT 208.8±5.6 152.8±15.6* 70.12±4.5* 59.71±4.9* 112±17.4* 45.66±4.1* 35.4±3.5* 
INDO 245±21 185±14* 61.1±4* 64.2±6.1* 145.2±12.2* 52.3±6.1* 41±5* 
HR, Heart Rate (Beats/min); LVDP, Left Ventricular Developed Pressure; RPP, Rate Pressure Product; I/R, Ischemia/Reperfusion; OT, 
Oxytocin; ATO, Atosiban; 5HD, 5-hydroxydecanoic acid; INDO, Indomethacin. Data are presented as mean±SEM. P<0.05 compared to their 
baselines. 
* P<0.05 vs. IR group and $ P<0.05 vs. OT group 
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induced cardioprotection is related to oxidative stress 
reduction (14). 
mKATP channels are the end-effectors of 
myocardial protection in postconditioning (32). When 
these channels are activated, they may reduce the 
action potential duration, decrease Ca2+ influx and 
cellular Ca2+ overload and increase myocyte survival 
during ischemia (32,43-44). Recent studies have 
suggested that mKATP channels play a pivotal role in 
postconditioning (32). Yang et al., indicated that non-
selective KATP channel inhibitor, glibenclamide and 
the putatively selective mKATP channel inhibitor, 
5HD abolished postconditioning protection in the 
rabbit heart (6). In the present study, we showed that 
OT can induce the postconditioning cardioprotective 
effect in rat heart and 5HD abolished the 
cardioprotective effects of OT, which indicates the 
contribution of mKATP channel opening in OT 
postconditioning. We showed that 5HD administration 
prior to OT infusion could increase infarct size; LDH 
and MDA levels compared to the OT group, but could 
not induce significant changes in hemodynamic 
parameter. Some studies showed that the signaling 
pathway initiated by G-protein coupled receptor 
activates the PKG, then activates the mitochondrial 
PKC-ε and leading to mKATP channel opening at 
postconditioning (32,45-46). The actual mechanism 
leading to mKATP channel opening is unclear. PKG 
and PKC activators, NO, and pharmacological agents 
have been identified as mKATP channel activators (47-
48). The relation between NO and the mKATP channel 
modulation was seen in the various studies (49-50). 
Sasaki et al., indicated that NO itself can modulate the 
opening of the mKATP channel (51). Since current 
results showed that OT postconditioning effect occurs 
via NO production, therefore NO release may have a 
pivotal role in mKATP channel activation through OT 
receptors and by this mechanism, it may protect the 
heart against I/R injury. 
Interactions exist between NO and PGs. NO can 
increase COX-1 and COX-2 activation. Endogenous NO 
and NO donors could increase PGs production. On the 
other hand, COX activation modulates NO pathway (52-
53). Recently, genetic and pharmacological studies 
showed that COX enzymes and their metabolites 
participate in the cardioprotection against I/R injuries. 
Ischemic injuries in COX-1 and COX-2 null mice hearts 
were increased, and this suggests that endogenous PGs 
might cause cardioprotection (17). It is also reported that 
ischemic postconditioning results in a rapid increase in 
COX-2 and myocardial contents of PGE2 and PGI2 (54-
55). The cardioprotective mechanism of increased COX-
2 activity is probably in part due to the increased levels 
of prostacyclin (18,54-55). The COX enzymes that 
involve in the cardiovascular system have complex and 
controversial roles. There is much clinical attention 
about COX pathways in myocardial infarction, and 
some studies propose that the increased level of COX-2 
and its products have a cardioprotective role in the 
ischemic preconditioning. In response to I/R, 
prostacyclin, released from cardiac tissue, which is 
synthesised partly, from COX-2 (21). Some studies have 
been reported that synthesis of PGI2 is increased 
especially during the 5–10 min of early reperfusion and 
then decreases quickly in the undefended myocardium 
(21). It was shown that bradykinin (BK) induced 
postconditioning can cause protection, and may allow 
COX activity and PGI2 formation in the late phase of 
reperfusion; therefore it can decrease reperfusion injury. 
In this study, we proposed that protection by OT 
postconditioning is likely due to increased COX activity. 
Iloprost induces cardioprotection during early 
reperfusion, which this protective role attributes to the 
production of PGs (21). However, a little knowledge is 
available about the actions of endogenous 
prostaglandins in the protective effect of OT 
postconditioning. Therefore, we evaluated, using 
indomethacin, whether prostaglandins are involved in 
the cardioprotection induced by OT postconditioning. 
Our results showed that indomethacin abolished the 
protective effects of OT completely, because there were 
no significant differences between INDO+OT group and 
I/R group. These data suggest that endogenously 
produced COX metabolites have protective role in OT 
postconditioning against I/R injury. The present study 
substantiates the concept that PGs are involved in 
cardioprotection. Since PGs can reduce infarct size via 
activation of PKC and KATP channels opening (56), 
and the interactions between NO and PGs and their 
effects on cardioprotection, it seems that OT via NO, 
PGs and mKATP channels opening could induce 
postconditioning cardioprotection. This study shows that 
postconditioning by OT can attenuate cardiac 
ischemia/reperfusion injury which readily is abolished 
by atosiban, 5HD, L-NAME and indomethacin. Thus, it 
may be concluded that the cardioprotective effects of 
OT is closely related to the activation of mKATP 
channel and increasing concentrations of endogenous 
NO and COX metabolites during reperfusion period in 
the isolated ischemic rat heart. 
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